63 million euro Series A round from SciRhom

The Munich-based biopharmaceutical company develops innovative antibodies against autoimmune diseases. The 63 million euros will be used to develop new autoimmune therapies.

Landshut, July 9, 2024 - Bayern Kapital, the venture and growth capital company of the Free State of Bavaria, has participated in a Series A financing round of the biopharmaceutical company SciRhom. The Munich-based company specializes in the development of therapies for autoimmune diseases. A total of 63 million euros was raised in this round.

International investors provide support

In addition to Bayern Kapital, Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital and Wellington Partners also participated in the increased and oversubscribed financing round. The new funds will flow into the further development of SciRhom's therapeutic strategy and the clinical proof of concept.

Innovative therapeutic approaches - the challenge of autoimmune diseases

SciRhom was founded in 2016 and is based at the Innovation and Start-up Center for Biotechnology (IZB) in Martinsried near Munich. The company develops therapeutic antibodies for autoimmune diseases. The approach is based on the research of co-founder Prof. Dr. Carl Blobel, an expert in the field of rheumatology and tissue degeneration.

Autoimmune diseases are the third most common group of diseases worldwide. They can cause severe damage to the affected organs. Treatment is often difficult because current drugs only attack individual signaling pathways. SciRhom is developing antibodies that block several signaling pathways simultaneously, which promises to be more effective.

Development of SR-878

SciRhom's lead candidate, SR-878, is a monoclonal antibody directed against the protein iRhom2. This protein influences the activity of the enzyme TACE/ADAM17, which plays an important role in inflammation and autoimmune diseases. Preclinical studies have already demonstrated the efficacy and safety of SR-878.

With SR-878, SciRhom has developed a novel approach with a new mechanism of action for the treatment of autoimmune diseases, which promises both higher efficacy and greater safety in terms of side effects.

Monika Steger, Managing Director of Bayern Kapital

Clinical studies in preparation

In November 2023, SciRhom submitted a clinical trial application for SR-878. The first Phase 1 trial is scheduled to begin in Austria in the second half of 2024. The aim of the study is to investigate the safety of the antibody in healthy volunteers and to obtain initial indications of clinical activity.

Future-oriented therapy development

With the support of renowned investors, SciRhom aims to push the boundaries of autoimmune medicine and develop effective and safe treatment options. The company is leveraging its expertise in the TACE/ADAM17 signaling pathway to develop innovative biopharmaceuticals.